MMMav Manji

Mav Manji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mav Manji has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hypotensive resuscitation

    by J. Geoghegan, A. Dennis, M. Manji

    Hypotensive resuscitation in the trauma setting can be defined as deliberately allowing blood pressure to remain below normal until any active bleeding has been controlled. The dangers of aggressive fluid resuscitation in trauma were recognised as long ago as the First World War, in the intervening time, aggressive fluid resuscitation has become a mainstay of trauma management. More recently this trend of aggressive fluid resuscitation for trauma management seems to be reversing. Aggressive fluid resuscitation in trauma is based on animal studies from the 1950s and 1960s. These studies used models of controlled haemorrhage rather than uncontrolled haemorrhage. More recent studies using models of uncontrolled haemorrhage suggest an improved outcome with hypotensive resuscitation. Should there be a potential for uncontrolled haemorrhage a permissive hypotensive resuscitation strategy should be pursued until the haemorrhage has been controlled, but in certain types of trauma including blunt trauma and brain trauma the data is unclear as to the best fluid resuscitation strategy.


  • Open Access

    Type XVIII collagen degradation products in acute lung injury

    by Gavin D Perkins, Nazim Nathani, Alex G Richter, Daniel Park, Murali Shyamsundar, Ritva Heljasvaara, Taina Pihlajaniemi, Mav Manji, W Tunnicliffe, Danny McAuley, et al.

    Introduction: In acute lung injury, repair of the damaged alveolar-capillary barrier is an essential part of recovery. Endostatin is a 20 to 28 kDa proteolytic fragment of the basement membrane collagen XVIII, which has been shown to inhibit angiogenesis via action on endothelial cells. We hypothesised that endostatin may have a role in inhibiting lung repair in patients with lung injury. The aims of the study were to determine if endostatin is elevated in the plasma/bronchoalveolar lavage fluid of patients with acute lung injury and ascertain whether the levels reflect the severity of injury and alveolar inflammation, and to assess if endostatin changes occur early after the injurious lung stimuli of one lung ventilation and lipopolysaccharide (LPS) challenge. Methods: Endostatin was measured by ELISA and western blotting. Results: Endostatin is elevated within the plasma and bronchoalveolar lavage fluid of patients with acute lung injury. Lavage endostatin reflected the degree of alveolar neutrophilia and the extent of the loss of protein selectivity of the alveolar-capillary barrier. Plasma levels of endostatin correlated with the severity of physiological derangement. Western blotting confirmed elevated type XVIII collagen precursor levels in the plasma and lavage and multiple endostatin-like fragments in the lavage of patients. One lung ventilation and LPS challenge rapidly induce increases in lung endostatin levels. Conclusions: Endostatin may adversely affect both alveolar barrier endothelial and epithelial cells, so its presence within both the circulation and the lung may have a pathophysiological role in acute lung injury that warrants further evaluation.


  • Open Access

    Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome

    by Nazim Nathani, Gavin D Perkins, William Tunnicliffe, Nick Murphy, Mav Manji, David R Thickett

    Background: Kerbs von Lungren 6 antigen (KL-6) is expressed on the surface of alveolar type II cells, and elevated plasma and epithelial lining fluid levels of KL-6 have previously been shown to correlate with the severity of disease and survival in acute respiratory distress syndrome (ARDS). The relationship between alveolar inflammation and KL-6 measurements has not been ascertained. We hypothesized that the elevation of KL-6 in ARDS is dependent upon the severity of neutrophilic inflammation. Furthermore we were interested in the relationship between significant alveolar infection and KL-6 levels. Methods: Plasma arterial samples were collected from ARDS patients on day 1 and when possible on day 4 along with bronchoalveolar lavage fluid (BALF) samples on the same day. Bacterial growth in the BALF was determined by quantitative cultures and was defined as significant at counts >1 × 104 colony-forming units. Results: Plasma KL-6 levels in ARDS patients were elevated compared with at-risk control individuals (P = 0.014) and with normal control individuals (P = 0.02). The plasma KL-6 level correlated with the Murray Lung Injury Score (r = 0.68, P = 0.001) and with BALF KL-6 (r = 0.3260, P = 0.04). The BALF KL-6 level was detectable in all ARDS cases and was lower on both day 0 and day 4 in those who survived. BALF KL-6 also correlated with the BALF myeloperoxidase activity (r = 0.363, P = 0.027), with the BALF cell count per millilitre (r = 0.318, P = 0.038), with BALF epithelial-cell-derived neutrophil attractant 78; (r = 0.37, P = 0.016) and with BALF vascular endothelial growth factor (r = 0.35, P = 0.024). The BALF KL-6 level of ARDS patients with significant pathogenic bacterial growth was similar compared with those without significant infection. Conclusion: KL-6 may represent a useful marker of alveolar type II cell dysfunction in ARDS since the levels reflect the severity of lung injury and neutrophilic inflammation. KL-6 release across the alveolar epithelial barrier is associated with a poor prognosis. The pathophysiological roles of KL-6 in the development of ARDS warrant further study.


  • Open Access

    Impact of introducing a sedation management guideline in intensive care

    by C. Adam, D. Rosser, M. Manji

    Summary: To ensure that sedative agents in the intensive care unit are used for maximum benefit, a guideline that promotes the accurate and continuous assessment of patients' needs is indicated. This observational 24‐month prospective study investigated the effect of introducing a sedation management guideline into a 10‐bedded multidisciplinary intensive care unit on length of stay, severity of illness, mortality and the number of bed days provided. Costs for all sedative drugs were calculated as cost per bed day. Intensive care unit mortality remained constant before and after guideline introduction. The length of stay of non‐cardiac surgery patients was mean (SD) 4.6 (4.4) and 5.1 (4.3) days, respectively (p = 0.2). Monthly sedative cost before guideline introduction was £6285 compared to £3629 afterwards (p≤0.0001), representing a real saving of £63 759 in sedative costs over the 2 years following introduction of the guideline. Guideline‐directed management for sedation significantly reduces the cost of sedative drugs per bed day without any negative effect on length of ICU stay and outcome.


  • Indications for endotracheal intubation and ventilation

    by Steve Christian, Mav Manji

    The ability of the emergency physician to recognize and manage a patient with a compromised airway is probably the most important aspect of an individual’s care in the emergency department. Endotracheal intubation in a critically ill patient is a potentially hazardous procedure because of the technical difficulties that can be encountered during emergency airway management and the profound pathophy siological changes that the institution of mechanical ventilation can cause. This review article sets out to illustrate when invasive airway management should be considered and the potential consequences of attempts to perform endotracheal intubation and mechanical ventilation.


  • Minimum haemoglobin in intensive care

    by Suneel Desai, Mav Manji

    Multiple and complex aetiological factors contributes to anaemia in critically ill patients. This article sets out to examine the clinical evidence and physiological rationale for transfusion, traditionally based on an arbitrary haemoglobin trigger of 10 g=dL. Maintenance of haemoglobin concentration level of 10 g=dL or above may benefit only a small group of patients with an acute myocardial infarction, unstable angina or those who have severe coronary artery disease. However, most critically ill patients tolerate anaemia very well due to physiological compen satory mechanisms and clinical studies suggest that there is an increase in adverse outcome if transfusion is carried out using this traditional trigger threshold.